Deucrictibant Immediate-release is a small molecule commercialized by Pharvaris, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Deucrictibant Immediate-release’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Deucrictibant Immediate-release is expected to reach an annual total of $205 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Deucrictibant Immediate-release Overview

Deucrictibant (PHVS-416) is under development for the treatment and prevention of hereditary angioedema (HAE). It is administered through oral route in the form of immediate-release (IR) softgel capsule. The drug candidate acts by targeting B2 bradykinin receptor (BDKRB2).

Pharvaris Overview

Pharvaris, is a clinical-stage biopharmaceutical company that develops and commercialization of innovative therapies for rare diseases. The company pipeline includes Deucrictibant (PHA121, PHA-022121) is a novel, small-molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). Pharvaris also evaluating and PHVS416, a soft gel capsule formulation and PHVS719, a tablet formulation for prophylactic treatment of bradykinin-mediated angioedema. The company works in collaboration with pharmaceutical for product development. The company operates in the US, Switzerland and the Netherlands. Pharvaris is headquartered in Leiden, Zuid-Holland, the Netherlands.
The operating loss of the company was EUR86.7 million in FY2022, compared to an operating loss of EUR54.1 million in FY2021. The net loss of the company was EUR76.3 million in FY2022, compared to a net loss of EUR42.7 million in FY2021.

For a complete picture of Deucrictibant Immediate-release’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.